The largest database of trusted experimental protocols

6 protocols using il 21

1

Generating CMV-Specific T Cell Lines and Clones

Check if the same lab product or an alternative is used in the 5 most similar protocols
CMV-specific T cell line (HD-2) and T cell clones (A1-8 and A1-9) specific for CMV pp65 protein were generated from a single HLA-A*0201+ healthy control. CMV-specific T cells were stained with HLA-PE-conjugated A*0201 CMVNLVPMVATV Dextramer (Immunex, Copenhagen, Denmark) for 30 min at room temperature. HLA-A*0201-CMV-CTL were then sorted using a FACS Aria flow cytometer.
Sorted CMV-CTL from HD-2 cell line were then clonally selected using limiting dilution in T cell medium containing Serum-free medium (Cell-Genix, Freiburg, Germany), with 10% human AB serum (Innovative Research, MI) supplemented with IL-2 (1000 IU/ml), IL-15 (10ng/ml), IL-21 (10ng/ml), (Prospec, Ness-Ziona, Israel), penicillin (100IU/ml), streptomycin (100μg/ml) (Life Technologies, Carlsbad, CA), and amphotericin B (2.5mg/L) (Sigma-Aldrich, St Louis, MO) and seeded with anti-CD3 (OKT3) (Biolegend, CA, USA) and addition of γ-irradiated allogeneic feeder cells at a 5:1 E:T ratio. After 14 days, the clonal selection was repeated. Expanded T cell clones were transferred into larger vessels when required where they were subsequently expanded in T cell culture medium and maintained by biweekly stimulation with OKT3 and irradiated allogenic feeder cells.
+ Open protocol
+ Expand
2

Polyclonal Activation and ELISpot Assay for H1N1 Virus

Check if the same lab product or an alternative is used in the 5 most similar protocols
Peripheral blood mononuclear cells collected at T0 and T1 from HIV and HC were thawed and polyclonally activated in vitro in complete RPMI medium (Invitrogen) supplemented with 2.5 µg/mL CpG type B (Hycult biotech), 20 ng/mL IL-4 (Peprotech), and 20 ng/mL IL-21 (ProSpec). Cells were harvested after 5 days of culture at 37°C. ELISpot 96-well filtration plates (Millipore) were coated with purified H1N1 inactivated virus particles and subsequently loaded with 2 × 105 cells/well. Plates were then processed as previously described (2 (link)). Response to H1N1 Ag was determined using the criteria ≥ or <80 spots/106 PBMCs in R and NR, respectively.
+ Open protocol
+ Expand
3

Glioma Patients' Immune Response Profiling

Check if the same lab product or an alternative is used in the 5 most similar protocols
Whole blood was obtained at the time of diagnosis from patients with gliomas (i.e., prior to surgery, radiation and chemotherapy), diluted 1:1.5 with RPMI 1640 l-glutamine (2 mM) with antibiotics (penicillin, 100 IU/mL, and streptomycin, 100 µg/mL) (Life Technologies, Carlsbad, USA) and incubated (i) without cytokines (RPMI only), (ii) with a IL-7 (10 ng/ml)/IL-2 (500 IU/ml) cytokine cocktail or (iii) with a IL-2 (1000 IU/ml)/IL-15 (10 ng/ml)/IL-21 (10 ng/ml) cytokine cocktail (Prospec, Ness Ziona, Israel). The diluted blood was co-incubated in pre-coated plates with a panel of different TAA and viral antigens (Supplementary Table 1) for 7 days at 37 °C and 5% CO2 as described previously [23 (link), 24 (link)]. To gauge the basal IFN-γ production to NY-ESO-1, survivin as well as commonly recognized target antigens, blood was incubated with medium (negative control) and non-tumor-related antigens, i.e., the Epstein–Barr virus nuclear antigen 3 (EBNA-3). Positive controls were phytohemagglutinin (PHA, Sigma-Aldrich), OKT3 (anti-CD3 monoAb, Biolegend, CA, USA, 30 ng/ml) and SEA + SEB (staphylococcal enterotoxin A and B). IFN-γ production was then quantified in the cell culture supernatant by ELISA (Mabtech, Stockholm, Sweden).
+ Open protocol
+ Expand
4

Polyclonal Activation of PBMCs for Influenza ELISpot

Check if the same lab product or an alternative is used in the 5 most similar protocols
PBMCs collected at T0 and T1 from HIV and HC were thawed and policlonally activated in vitro in complete RPMI medium (Invitrogen) supplemented with 2.5 μg/mL CpG type B (Hycult biotech), 20 ng/mL IL-4 (Peprotech) and 20 ng/mL IL-21 (ProSpec). Cells were harvested after 5 days of culture at 37°C. ELISpot 96-well filtration plates (Millipore) were coated with the addition of purified H1N1, H3N2, and B influenza inactivated virus particles and subsequently loaded with 2 × 105 cells/well. Membranes were punched out with an Eli.Punch device and developed spots were scanned with an Eli.Scan and counted with the ELISpot Analysis Software V5.1 (all from A.EL.VIS).
+ Open protocol
+ Expand
5

Quantifying T-cell Activation by ELISA

Check if the same lab product or an alternative is used in the 5 most similar protocols
Whole blood was first diluted at a ratio of 1:1.5 with either RPMI 1640 medium containing l-glutamine (2 mM) with antibiotics (100 IU/ml penicillin and 100 µg/ml streptomycin) (Life Technologies, Carlsbad, USA) alone or supplemented with the following cytokine cocktail: IL-2 (1000 IU/ml), IL-15 (10 ng/ml) and IL-21 (10 ng/ml) (Prospec, Ness-Ziona, Israel). Diluted blood was added in duplicates for each condition to 96-well plates pre-coated with the proteins EBNA-1 or CMV-pp65 (Prospec, Ness-Ziona, Israel) at a final concentration of 1 μg/ml and incubated for 7 days at 37 °C with 5% CO2 as previously described [26 (link), 27 (link)]. Antigen-free medium was used as negative control while phytohemagglutinin protein (PHA 5 μg/ml, Sigma Aldrich) was used positive control. Cell culture supernatants were harvested after the incubation period to quantify IFNγ production by sandwich ELISA (Mabtech, Stockholm, Sweden) according to the manufacturer’s instructions. Assay plates were analyzed using a Vmax kinetic microplate reader (Molecular Devices, USA) at 450 nm. After basal IFNγ production (medium only) subtraction, data were reported as absolute cytokine concentration values (pg/ml).
+ Open protocol
+ Expand
6

Expansion of Tumor-Infiltrating Lymphocytes from Glioma Tissue

Check if the same lab product or an alternative is used in the 5 most similar protocols
Plasma was removed following centrifugation of whole blood samples, and stored at -80°C. Glioma tumor tissue was harvested in the course of tumor surgery at the Department of Neuro-Oncology at Karolinska University Hospital, Stockholm. Tumor tissue was immediately transferred to Cellgro GMP Serum-free DC medium medium supplemented with 5% pooled human AB serum. Tumor tissue was dissected into fragments of approximately 1-2mm3 using a sterile scalpel, or processed into a tissue homogenate using the BD Medimachine. Tissue fragments of the cell suspension were washed twice with PBS and cultured in 24 well plates in Cellgro medium plus 5% pooled human AB serum supplemented with recombinant IL-2 (1000IU/ml), IL-15(10ng/ml) and IL-21 (10ng/ml) (Prospec, Ness-Ziona, Israel). Medium was changed as necessary. Irradiated (55Gy) feeder cells (allogeneic PBMCs) at the ratio of 1 (feeder cells):10 (TILs) was added on day 7. OKT3 (anti-CD3 monoclonal antibody, BioLegend, San Diego, CA) was used at 10ng/ml as TILs became visible under the microscope. TILs were transferred to 6-well plates; upon achieving > 70% confluence in the 24-well surface. They were further expanded in G-Rex flasks (Wilson Wolf, New Brighton, MN) using 30ng OKT3/mL and irradiated (55Gry) allogeneic feeder cells at the ratio of 1 (feeder cells):10 (TILs).
+ Open protocol
+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required

Sign up now

Revolutionizing how scientists
search and build protocols!